Patrick C. Ma, MD, MSc

Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program, WVU Cancer Institute, West Virginia University, Morgantown, WV, USA

Dr. Patrick C. Ma joined West Virginia University Mary Babb Randolph Cancer Center in Morgantown, WV, USA in December 2014 where he was appointed to be the co-leader of the endowed Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program, Eminent Scholar in Lung Cancer Research, and Associate Professor of Medicine. Prior to WVU, he held the position as Director of Aerodigestive Oncology Translational Research Program and Staff Thoracic Oncologist at the Taussig Cancer Institute, Cleveland Clinic in Ohio, USA from 2010-2014. Dr. Ma was also previously faculty member at the Case Western Reserve University/University Hospitals Case Medical Center (2005-2010); and the University of Chicago Pritzker School of Medicine (2003-2005). Dr. Ma graduated his medical education (M.D.) at the University of Toronto, Ontario, Canada, where he also completed postgraduate studies in Biochemistry and Family Medicine board certification, before relocating in 1996 to Boston, U.S. Subsequently, Dr. Ma further completed his Internal Medicine residency and then subspecialty postgraduate fellowship training in Hematology-Oncology at Tufts-New England Medical Center, and also Thoracic Oncology Research Fellowship at Dana-Farber Cancer Institute in Boston, MA.

Dr. Ma has a special interest in thoracic malignancies. He is Director of the Clinical Lung Cancer Program at WVU, and also leads laboratory-based translational and clinical research in thoracic oncology, with an emphasis on cancer genomics, cancer metabolomics and personalized molecularly targeted- and immuno-therapies. Dr. Ma’s particular research focuses include oncogenic kinase signaling, mutational analysis and profiling of molecular/genomic therapeutic targets of lung cancer, and also genomic determinants of precision therapy sensitivity and resistance. He has considerable expertise in MET/HGF targeting therapy in lung cancer. Through his research endeavors, he has been awarded a number of competitive awards and research grants. Dr. Ma has also been named Best Doctor (Medical Oncology) by the Cleveland Magazine 2013-2014. Dr. Ma is principal investigator or co-investigator in several lung cancer clinical trials investigating novel targeted therapeutics in lung cancer. He was recipient of a Department of Defense (DOD) Lung Cancer Promising Clinician Research Award. Dr. Ma has also authored and co-authored numerous peer-reviewed article, reviews and book chapters. His research work has been published in Cancer Research, Clinical Cancer Research, Oncotarget, Nature Genetics, Cancer Discovery, and New England Journal of Medicine. Dr. Ma serves as scientific program committee member in the Tumor Biology Track of the ASCO Annual Meeting (2015-2018) and is the Tumor Biology track leader in 2018.